• Rui Ji, Qian Ren, Suyang Bai, Yuping Wang, and Yongning Zhou.
• Department of Gastroenterology, the First Hospital of Lanzhou University Key Laboratory for Gastrointestinal Diseases of Gansu Province, Lanzhou University, Lanzhou, China.
• Medicine (Baltimore). 2018 Jun 1; 97 (25): e10824e10824.

BackgroundThe high pretreatment plasma fibrinogen has been widely reported to be a possible biomarker for predicting prognosis in hepatocellular carcinoma (HCC) and pancreatic carcinoma (PC), but persuasive conclusion has not been made yet. Thus, we herein conducted a meta-analysis to comprehensively assess the prognostic value of high pretreatment plasma fibrinogen in patients with HCC and PC.MethodWe systematically searched PubMed, EMBASE, and Web of Science to identify eligible studies from inception to November 10, 2017.ResultsFinally, a total of 12 publications with 13 studies were included. Of these eligible studies, 5 publications with 6 studies were about pancreatic cancer and 7 were about HCC. The pooled analysis indicated that high plasm fibrinogen level was significantly related to worse overall survival (OS) in HCC [hazard ratio (HR) = 1.87; 95% confidence interval (CI): 1.55-2.24; P < .01]. Similarly, from our result, it was found that high plasm fibrinogen was also significantly associated with worse OS in PC (HR = 1.56; 95% CI: 1.13-2.15; P < .01).ConclusionTaken together, our meta-analysis confirmed that high plasma fibrinogen level could predict worse survival in HCC and PC.

21 keywords...

hide…